{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-012566","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.659511+00:00","generated_at":"2026-06-17T01:23:12.366817+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BriaCell presents positive Bria-IMT data at AACR; 15/18 alive, immune activation in anergic patients","bullets":["15 of 18 patients enrolled since 2021 remain alive; survival compares favorably to 6.7-9.8 months in similar studies.","PFS benefit: most patients had PFS similar or higher than prior therapy, suggesting better tolerability and clinical effectiveness.","Immune activation in 70% of anergic patients (weak immune systems) and 89% of non-anergic after Bria-IMT combo.","8 of 17 HR+ patients (large segment) experienced PFS benefit; no immunotherapies shown to work in HR+ breast cancer.","Next-gen Bria-OTS2.0 significantly more effective than Bria-OTS in activating naïve T-cells; planned for Phase I/IIa."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-012566","json":"https://secwatch.observer/filing/0001493152-23-012566.json","markdown":"https://secwatch.observer/filing/0001493152-23-012566.md","text":"https://secwatch.observer/filing/0001493152-23-012566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223012566/0001493152-23-012566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223012566/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:23:12.366817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}